Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice?

Stewart PM.

J Endocr Soc. 2019 Apr 11;3(6):1150-1153. doi: 10.1210/js.2019-00046. eCollection 2019 Jun 1. Review.

2.

Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments.

Johannsson G, Skrtic S, Lennernäs H, Quinkler M, Stewart PM.

Curr Med Res Opin. 2014 Sep;30(9):1833-47. doi: 10.1185/03007995.2014.925865. Epub 2014 Jun 9. Review.

PMID:
24849526
3.

Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency.

Oprea A, Bonnet NCG, Pollé O, Lysy PA.

Ther Adv Endocrinol Metab. 2019 Feb 2;10:2042018818821294. doi: 10.1177/2042018818821294. eCollection 2019. Review.

4.

Is physiological glucocorticoid replacement important in children?

Porter J, Blair J, Ross RJ.

Arch Dis Child. 2017 Feb;102(2):199-205. doi: 10.1136/archdischild-2015-309538. Epub 2016 Aug 31. Review.

5.

European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.

Ekman B, Fitts D, Marelli C, Murray RD, Quinkler M, Zelissen PM.

BMC Endocr Disord. 2014 May 9;14:40. doi: 10.1186/1472-6823-14-40.

6.

Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy.

Chan S, Debono M.

Ther Adv Endocrinol Metab. 2010 Jun;1(3):129-38. doi: 10.1177/2042018810380214.

7.

Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors.

Lennernäs H, Skrtic S, Johannsson G.

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):749-58. doi: 10.1517/17425255.4.6.749 . Review.

PMID:
18611115
8.

Modified-release hydrocortisone to provide circadian cortisol profiles.

Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ.

J Clin Endocrinol Metab. 2009 May;94(5):1548-54. doi: 10.1210/jc.2008-2380. Epub 2009 Feb 17.

9.

Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.

Weigel M, Hahner S, Sherlock M, Agha A, Behan LA, Stewart PM, Arlt W, Beier D, Frey K, Zopf K, Quinkler M.

Clin Endocrinol (Oxf). 2017 Apr;86(4):499-505. doi: 10.1111/cen.13302. Epub 2017 Feb 3.

PMID:
28063163
10.

Novel strategies for hydrocortisone replacement.

Debono M, Price JN, Ross RJ.

Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):221-32. doi: 10.1016/j.beem.2008.09.010. Review.

PMID:
19500765
11.

Therapeutic innovations in endocrine diseases - Part 2: Modified-release glucocorticoid compounds: What good do they provide to the adrenal insufficient patient?

Reznik Y.

Presse Med. 2016 Jun;45(6 Pt 2):e205-10. doi: 10.1016/j.lpm.2016.05.007. Epub 2016 May 31. Review.

PMID:
27260966
12.

Therapy of adrenal insufficiency: an update.

Falorni A, Minarelli V, Morelli S.

Endocrine. 2013 Jun;43(3):514-28. doi: 10.1007/s12020-012-9835-4. Epub 2012 Nov 21. Review.

PMID:
23179775
13.

Improving glucocorticoid replacement profiles in adrenal insufficiency.

Choudhury S, Lightman S, Meeran K.

Clin Endocrinol (Oxf). 2019 Apr 24. doi: 10.1111/cen.13999. [Epub ahead of print] Review.

PMID:
31017681
14.

Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment.

Paragliola RM, Corsello SM.

Minerva Endocrinol. 2018 Jun;43(2):183-197. doi: 10.23736/S0391-1977.17.02701-8. Epub 2017 Jul 27. Review.

15.

Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers.

Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ.

Clin Endocrinol (Oxf). 2008 Jan;68(1):130-5. Epub 2007 Sep 4.

PMID:
17803699
16.

Doses and steroids to be used in primary and central hypoadrenalism.

Debono M, Ross RJ.

Ann Endocrinol (Paris). 2007 Sep;68(4):265-7. Epub 2007 Jul 24. Review.

PMID:
17651687
17.

Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.

Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ.

Clin Endocrinol (Oxf). 2006 Jul;65(1):45-50.

PMID:
16817818
18.

Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency.

Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, Øksnes M.

Eur J Endocrinol. 2015 May;172(5):619-26. doi: 10.1530/EJE-14-1114. Epub 2015 Feb 5.

PMID:
25656494
19.

Recent Advances in Hydrocortisone Replacement Treatment.

Mallappa A, Debono M.

Endocr Dev. 2016;30:42-53. doi: 10.1159/000439329. Epub 2015 Dec 10. Review.

PMID:
26683495
20.

Long-acting hydrocortisone for glucocorticoid replacement therapy.

Johannsson G, Filipsson H, Bergthorsdottir R, Lennernäs H, Skrtic S.

Horm Res. 2007;68 Suppl 5:182-8. doi: 10.1159/000110621. Epub 2007 Dec 10. Review.

PMID:
18174742

Supplemental Content

Support Center